Currency In USD
| Previous Close | 12.56 |
| Open | 12.13 |
| Day High | 13.07 |
| Day Low | 12.09 |
| 52-Week High | 26.95 |
| 52-Week Low | 3.71 |
| Volume | 912,922 |
| Average Volume | 1.44M |
| Market Cap | 1.06B |
| PE | -22.96 |
| EPS | -0.55 |
| Moving Average 50 Days | 13.8 |
| Moving Average 200 Days | 11.88 |
| Change | 0.07 |
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
GlobeNewswire Inc.
Mar 05, 2026 9:01 PM GMT
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 23, 2026 9:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with invest
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
GlobeNewswire Inc.
Jan 23, 2026 10:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of it